Capital Fund Management S.A. Purchases Shares of 183,796 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Capital Fund Management S.A. purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 183,796 shares of the company's stock, valued at approximately $1,242,000.

Other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its stake in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares during the period. Wedmont Private Capital boosted its stake in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock worth $144,000 after buying an additional 2,000 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock valued at $69,000 after buying an additional 2,235 shares during the period. Green Alpha Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company's stock valued at $454,000 after buying an additional 2,346 shares in the last quarter. Finally, Xponance Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 22.2% during the 4th quarter. Xponance Inc. now owns 19,163 shares of the company's stock worth $130,000 after acquiring an additional 3,480 shares during the period. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on RXRX shares. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Trading Up 3.4 %

Shares of NASDAQ:RXRX traded up $0.18 during trading on Friday, hitting $5.50. 12,710,040 shares of the company's stock were exchanged, compared to its average volume of 12,004,554. The firm has a 50-day moving average price of $6.66 and a two-hundred day moving average price of $6.80. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The firm has a market cap of $2.21 billion, a P/E ratio of -3.59 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.42) earnings per share. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.